Tesamorelin: Uses, Mechanism, and Side Effects

If you have heard about tesamorelin in the context of HIV treatment and excess abdominal fat, you likely want to know what it actually does and how well it is studied. This peptide has an FDA-approved indication, a defined mechanism, and a real body of clinical and post-marketing data behind it.

Key takeaways

• Tesamorelin is approved under the brand name EGRIFTA SV for reducing excess abdominal fat in HIV-infected adults with lipodystrophy.
• It works by mimicking growth hormone-releasing factor (GHRF) to stimulate the body's own growth hormone release.
• It is not approved for general weight loss and has a weight-neutral effect overall.
• At least 24 clinical trials have studied tesamorelin, including completed Phase 3 work in HIV-associated lipodystrophy.
• The most frequently reported issues in post-marketing data relate to dosing errors and injection site reactions, not systemic toxicity.

What Tesamorelin Is

Tesamorelin is a synthetic analog of growth hormone-releasing factor (GHRF), also called growth hormone-releasing hormone. In laboratory studies, it binds to and activates the same pituitary receptors as the body's natural GHRF, prompting the pituitary gland to release growth hormone in its normal pulsatile pattern. Growth hormone released this way has both tissue-building (anabolic) and fat-breakdown (lipolytic) effects, which is the basis for tesamorelin's use in reducing abdominal fat.

What Tesamorelin Is Approved For

Tesamorelin, marketed as EGRIFTA SV, is approved for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The label specifies that it is not approved as a weight loss treatment because it does not reduce overall body weight. It also notes that long-term cardiovascular safety has not been established, and clinicians are advised to weigh the risks and benefits of continued treatment if visceral fat does not decrease. There is no evidence that tesamorelin improves adherence to antiretroviral therapy. No boxed warning is present on the label.

What the Evidence Shows

Tesamorelin has been studied in at least 24 registered clinical trials. A completed Phase 3 trial examined tesamorelin (then known as TH9507) in patients with HIV-associated lipodystrophy, supporting its approved use. Other research has explored different populations, including a Phase 1 study on cognitive function in people with mild cognitive impairment and a Phase 2 trial in COPD patients with muscle wasting that was later terminated.

Reported Side Effects

Post-marketing reports for tesamorelin most commonly involve dosing and administration issues rather than classic adverse drug reactions, including product dose omission (297 reports) and incorrect dose administered (164 reports). Injection site reactions are also frequently reported, with pain (160 reports) and bruising (99 reports) among the most common. Other reported issues include drug ineffectiveness (130 reports), joint pain (113 reports), and weight increase (99 reports). These figures represent counts of submitted reports, not confirmed incidence rates or established causation.